Bradley Saenger's Net Worth
-$4.74 Thousand
Who is Bradley Saenger?
Bradley Saenger does not have any significant net worth to report based on the numbers we have. This is based on reported shares in Tonix Pharmaceuticals Holding Corp..
SEC CIK
Bradley Saenger's CIK is 0001668150
Past Insider Trading and Trends
2019 was Bradley Saenger's most active year for acquiring shares with 4 total transactions. Bradley Saenger's most active month to acquire stocks was the month of January. 2016 saw Bradley Saenger paying a total of $4,000.00 for 82,000 shares, this is the most they've acquired in one year.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Tonix Pharmaceuticals Holding Corp. (TNXP) Snapshot price: $0.16
Chief Financial OfficerBradley Saenger owns 3,079 units of Common Stock, $0.001 par value which is worth $492.64. From 2016 to 2024 Bradley Saenger acquired a total of 2,300 shares in Tonix Pharmaceuticals Holding Corp. at a cost of $5,230.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 26
| |||
Form 4
| +10.80% | 300 |
$4.10 | $1,230.00 | 3.08K |
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 13
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 1
| |||
Form 4
| +49.52% | 2K |
$2.00 | $4,000.00 | 6.04K |
Jun 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 27
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||